The publication titled, “Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor (ETI) suggest benefits beyond improved CFTR channel function” was highlighted in Cystic Fibrosis News Today.
Coauthors: Thomas Hampton, Roxanna Barnaby, Carolyn Roche, Amanda Nymon, Kiyoshi Ferreira Fukutani, Todd MacKenzie, Lily Charpentier and Bruce Stanton
The study reports that ETI, also called Trikafta, may ease inflammation, tissue damage and reduce cell stress in the lungs of people with Cystic Fibrosis.
Full Article: Trikafta may work to ease inflammation, tissue damage in CF lungs